- Home
- CYRX vs CGEM Comparison
CYRX vs CGEM Comparison
Compare CYRX & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYRX | CGEM |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | 1100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 883.3M | 999.4M |
| IPO Year | 2008 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CYRX | CGEM |
|---|---|---|
| Price | $18.32 | $15.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $19.78 | ★ $34.60 |
| AVG Volume (30 Days) | 656.8K | ★ 769.3K |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.22 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $176,177,000.00 | N/A |
| Revenue This Year | $10.95 | N/A |
| Revenue Next Year | $10.11 | $300.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.61 | $6.73 |
| 52 Week High | $18.88 | $23.19 |
Technical Indicators
Market Signals| Indicator | CYRX | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 58.68 | 48.11 |
| Support Level | $14.55 | $12.73 |
| Resistance Level | N/A | $16.31 |
| Average True Range (ATR) | 0.71 | 0.86 |
| MACD | 0.09 | 0.33 |
| Stochastic Oscillator | 78.17 | 77.89 |
Price Performance
Historical ComparisonAbout CYRX CryoPort Inc.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.